Literature DB >> 31832914

Perioperative Detection of Circulating Tumor Cells in Radical or Partial Nephrectomy for Renal Cell Carcinoma.

Nobuhiro Haga1, Akifumi Onagi2, Tomoyuki Koguchi2, Seiji Hoshi2, Soichiro Ogawa2, Hidenori Akaihata2, Junya Hata2, Hiroyuki Hiraki2, Ruriko Honda2, Ryo Tanji2, Kanako Matsuoka2, Masao Kataoka2, Yuichi Sato2, Kei Ishibashi2, Yoshiyuki Kojima2.   

Abstract

BACKGROUND: The current study was conducted to clarify the frequency of systemic circulating tumor cells (CTCs) appearing after surgery for renal cell carcinoma and to evaluate the differences in postoperative CTCs between different surgical procedures.
METHODS: This prospective, cohort study included 60 consecutive patients who underwent laparoscopic radical nephrectomy (RN) (n = 22), laparoscopic partial nephrectomy (PN) (n = 19), open RN (n = 8), or open PN (n = 11). In this study CTCs were measured by the FISHMAN-R system, and CTCs drawn from a peripheral artery were collected just before and immediately after surgery. The number of pre- and postoperative CTCs and the perioperative changes in CTCs were measured for each surgical method.
RESULTS: Six patients were excluded from the current analyses. Preoperative CTCs did not differ significantly by surgical approach (laparoscopic RN: 3.4 ± 4.2; laparoscopic PN: 3.4 ± 4.1; open RN: 7.7 ± 6.8; open PN: 6.0 ± 7.6; P = 0.19). Open RN resulted in a significantly greater number of postoperative CTCs (laparoscopic RN: 4.8 ± 3.7; laparoscopic PN: 7.9 ± 9.1; open RN: 22.5 ± 26.3; open PN: 6.4 ± 6.3; P < 0.001) and perioperative changes in CTCs (laparoscopic RN: 1.3 ± 5.3; laparoscopic PN: 4.5 ± 9.6; open RN: 14.7 ± 25.0; open PN: 0.4 ± 6.3; P < 0.001). No significant differences in these were observed among the three groups except in the open RN group. In the multivariate analysis, the surgical approach was significantly correlated with the number of postoperative CTCs (P = 0.016) and the perioperative change in CTCs (P = 0.01).
CONCLUSIONS: This proof-of-concept study indicated that after surgery, more cancer cells can be expelled into the bloodstream, especially after open RN. Sufficient and careful follow-up assessment for the emergence of distant metastases is needed for patients undergoing open RN.

Entities:  

Mesh:

Year:  2019        PMID: 31832914     DOI: 10.1245/s10434-019-08127-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  [Electrophoress of serum proteins in Sydenham's chorea].

Authors:  A Dudkowska; W Kawiak
Journal:  Neurol Neurochir Pol       Date:  1970 Sep-Oct       Impact factor: 1.621

2.  Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma.

Authors:  Angela Gradilone; Roberto Iacovelli; Enrico Cortesi; Cristina Raimondi; Walter Gianni; Chiara Nicolazzo; Arianna Petracca; Antonella Palazzo; Flavia Longo; Luigi Frati; Paola Gazzaniga
Journal:  Anticancer Res       Date:  2011-12       Impact factor: 2.480

  2 in total
  8 in total

1.  ASO Author Reflections: Increase of Circulating Tumor Cells After Open Radical Nephrectomy Compared with Other Surgical Modalities.

Authors:  Nobuhiro Haga
Journal:  Ann Surg Oncol       Date:  2020-01-13       Impact factor: 5.344

2.  The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer.

Authors:  Consuelo Amantini; Federica Maggi; Jacopo Adolfo Rossi de Vermandois; Marilena Gubbiotti; Antonella Giannantoni; Ettore Mearini; Massimo Nabissi; Daniele Tomassoni; Giorgio Santoni; Maria Beatrice Morelli
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

3.  Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma.

Authors:  Jinbo Song; Zhe Yu; Bingqi Dong; Mingkai Zhu; Xiaofeng Guo; Yongkang Ma; Shiming Zhao; Tiejun Yang
Journal:  World J Surg Oncol       Date:  2021-05-25       Impact factor: 2.754

Review 4.  Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer.

Authors:  Alessia Cimadamore; Gaetano Aurilio; Franco Nolé; Francesco Massari; Marina Scarpelli; Matteo Santoni; Antonio Lopez-Beltran; Liang Cheng; Rodolfo Montironi
Journal:  Cells       Date:  2020-06-19       Impact factor: 6.600

Review 5.  Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art.

Authors:  Michele Marchioni; Juan Gomez Rivas; Anamaria Autran; Moises Socarras; Simone Albisinni; Matteo Ferro; Luigi Schips; Roberto Mario Scarpa; Rocco Papalia; Francesco Esperto
Journal:  Curr Urol Rep       Date:  2021-04-22       Impact factor: 3.092

6.  Wedge resection before lobectomy for patients with T1N0M0 non-small cell lung cancer: a propensity score matching analysis.

Authors:  Yuan Zeng; Ying Huang; Junhui Fu; Ke Xu; Wenhua Liang; Fei Cui; Zhexue Hao; Xukai Li; Tuo Xing; Jianxing He; Jun Liu
Journal:  Ann Transl Med       Date:  2022-05

7.  The Diagnostic Value of Serum Ang, VEGF, and CRP Combined with the Chinese Medicine Antitumor Formula in the Treatment of Advanced Renal Carcinoma.

Authors:  Nana Dong; Shengmin Zhang; Shuangjun Zhang; Qiongqiong Zhao; Donghua Zhang; Feng Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-14       Impact factor: 2.629

Review 8.  Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs).

Authors:  Trevor J Mathias; Katarina T Chang; Stuart S Martin; Michele I Vitolo
Journal:  Cancers (Basel)       Date:  2020-03-21       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.